Cancers 2012, 4(1), 88-99; doi:10.3390/cancers4010088
Review

Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality

1 Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 65-Tsurumai, Showa, Nagoya 466-8550, Japan 2 Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan
* Author to whom correspondence should be addressed.
Received: 21 November 2011; in revised form: 4 January 2012 / Accepted: 3 February 2012 / Published: 7 February 2012
(This article belongs to the Special Issue Desmoid Tumors)
PDF Full-text Download PDF Full-Text [505 KB, uploaded 7 February 2012 13:23 CET]
Abstract: Treatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. We reviewed the previously reported outcomes of surgical and conservative treatment in our institutions. Among 30 patients receiving surgical treatment, 16 (53%) recurred. Younger age ( p < 0.05) was a significant poor factor. According to RECIST for meloxicam treatment, CR was in one, PR in 10, SD in eight, PD in one evaluated at 2011. Older age ( p < 0.01) was significantly associated with good outcome for meloxicam treatment. Results of the previous study indicated that surgical treatment alone could not control desmoid tumors, even with negative surgical margin. Considering the functional impairment resulting from surgery with negative surgical margin, a conservative and effective treatment modality with fewer complications is desired. Conservative treatment with meloxicam is a promising novel modality for patients with extra-abdominal desmoid tumors.
Keywords: extra-abdominal desmoids; meloxicam; COX-2; conservative therapy; surgery

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Nishida, Y.; Tsukushi, S.; Shido, Y.; Urakawa, H.; Arai, E.; Ishiguro, N. Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality. Cancers 2012, 4, 88-99.

AMA Style

Nishida Y, Tsukushi S, Shido Y, Urakawa H, Arai E, Ishiguro N. Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality. Cancers. 2012; 4(1):88-99.

Chicago/Turabian Style

Nishida, Yoshihiro; Tsukushi, Satoshi; Shido, Yoji; Urakawa, Hiroshi; Arai, Eisuke; Ishiguro, Naoki. 2012. "Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality." Cancers 4, no. 1: 88-99.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert